The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIII.a

Bronchospasm - Wheezing - Asthma

Publications

Torres D, Parrinello G, Paterna S, Bellanca M, Licata G

Severe Brochostenosis by Oral Propafenone Immediately After Commencing Treatment.

American journal of therapeutics 2011 Jan 18;; — 2011 Jan 18

Hill MR, Gotz VP, Harman E, McLeod I, Hendeles L

Evaluation of the asthmogenicity of propafenone, a new antiarrhythmic drug. Comparison of spirometry with methacholine challenge.

Chest 1986 Nov;90;698-702 — 1986 Nov — 698-702

Olm M, Munne P, Jimenez MJ

Severe reactive airways disease induced by propafenone.

Chest 1989 Jun;95;1366-7 — 1989 Jun — 1366-7